Who owns HTL Biotechnology?

HTL Biotechnology is formerly owned by Bridgepoint, through Europe V (BE V), since 2018.

When did Bridgepoint acquire HTL Biotechnology?

Bridgepoint acquired HTL Biotechnology in 2018 and exited after 4 years.

Has HTL Biotechnology been sold?

Yes. HTL Biotechnology was exited in 2022 via Secondary.

Home/Companies/Healthcare/HTL Biotechnology

HTL Biotechnology

Healthcare·

France·Exited 2022·Held 4yr

HTL Biotechnology is a healthcare company, headquartered in France.

Entry

2018

Hold

4yr

Exit

2022

Est. EV

€1.2B

Most recent investor

Bridgepoint

2 ownership periods

Key facts

HQFrance

SectorHealthcare

World pioneer in pharma-grade hyaluronic acid bioproduction (fermentation, not animal-derived). Entry ~€250M from Naxicap (Oct 2018), exit…Read full notes

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

5 verified KPIs (Revenue, EBITDA, growth)

5 source links for every datapoint

Full fund context: vintage, strategy, region

6 portfolio peers in Europe V (BE V)

Data refreshed weekly · Sourced from public filings